A Study Evaluating the Real World Experience of Participants Treated With BRIUMVI® (Ublituximab-xiiy) for Relapsing Multiple Sclerosis (RMS)

Conditions

• Multiple Sclerosis
• Relapsing Multiple Sclerosis

Eligibility Criteria

Sex

ALL

Age

18 Years - N/A

Healthy Volunteers

Not accepted

Interventions

• No Intervention — OTHER
  No Intervention

Study Details

The purpose of this study is to evaluate safety, effiectiveness, and to gain insight into the treatment experience of participants prescribed BRIUMVI® (ublituximab-xiiy) in the real-world setting

Key Dates

Start date

Jul 22, 2024

Status verified

May 2026

Primary completion

Apr 1, 2032

Completion

Apr 1, 2032

Study Design

Enrollment

2,000 participants (estimated)

Arms

• Arm: BRIUMVI® (Ublituximab-xiiy)
  Participants will receive BRIUMVI® (Ublituximab-xiiy) intravenous (IV) infusion for the treatment of RMS.

Primary Outcome Measure

Annualized Relapse Rate (ARR) [ Time Frame: Up to Week 96 ]

Central Contacts

• TG Therapeutics Clinical Support Team
  1-877-575-8489
  [email protected]

Locations (87)

Find similar trials in Birmingham, AL

Related Studies

• Magnetic Resonance Imaging (MRI) to Evaluate Activity of Multiple Sclerosis (MS)
  Recruiting · National Institute of Neurological Disorders and Stroke (NINDS) · Bethesda, Maryland
• Serum Auto-Antibodies in Neurological Diseases
  Enrolling By Invitation · University of California, Davis · Sacramento, California
• Comprehensive Multimodal Analysis of Neuroimmunological Diseases of the Central Nervous System
  Recruiting · National Institute of Allergy and Infectious Diseases (NIAID) · Bethesda, Maryland
• NARCOMS Registry: A Multiple Sclerosis Registry
  Recruiting · University of Texas Southwestern Medical Center · Dallas, Texas